Cargando…

Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome

A subunit vaccine, RBD-S, is under development to prevent severe acute respiratory syndrome (SARS) caused by SARS coronavirus (SARS-CoV), which is classified by the US NIH as a category C pathogen. This vaccine is comprised of a recombinant receptor-binding domain (RBD) of the SARS-CoV spike (S) pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Shibo, Bottazzi, Maria Elena, Du, Lanying, Lustigman, Sara, Tseng, Chien-Te Kent, Curti, Elena, Jones, Kathryn, Zhan, Bin, Hotez, Peter J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586247/
https://www.ncbi.nlm.nih.gov/pubmed/23252385
http://dx.doi.org/10.1586/erv.12.126
_version_ 1782261285917818880
author Jiang, Shibo
Bottazzi, Maria Elena
Du, Lanying
Lustigman, Sara
Tseng, Chien-Te Kent
Curti, Elena
Jones, Kathryn
Zhan, Bin
Hotez, Peter J
author_facet Jiang, Shibo
Bottazzi, Maria Elena
Du, Lanying
Lustigman, Sara
Tseng, Chien-Te Kent
Curti, Elena
Jones, Kathryn
Zhan, Bin
Hotez, Peter J
author_sort Jiang, Shibo
collection PubMed
description A subunit vaccine, RBD-S, is under development to prevent severe acute respiratory syndrome (SARS) caused by SARS coronavirus (SARS-CoV), which is classified by the US NIH as a category C pathogen. This vaccine is comprised of a recombinant receptor-binding domain (RBD) of the SARS-CoV spike (S) protein and formulated on alum, together with a synthetic glucopyranosyl lipid A. The vaccine would induce neutralizing antibodies without causing Th2-type immunopathology. Vaccine development is being led by the nonprofit product development partnership; Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development in collaboration with two academic partners (the New York Blood Center and University of Texas Medical Branch); an industrial partner (Immune Design Corporation); and Walter Reed Army Institute of Research. A roadmap for the product development of the RBD-S SARS vaccine is outlined with a goal to manufacture the vaccine for clinical testing within the next 5 years.
format Online
Article
Text
id pubmed-3586247
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-35862472013-10-01 Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome Jiang, Shibo Bottazzi, Maria Elena Du, Lanying Lustigman, Sara Tseng, Chien-Te Kent Curti, Elena Jones, Kathryn Zhan, Bin Hotez, Peter J Expert Rev Vaccines Special Report A subunit vaccine, RBD-S, is under development to prevent severe acute respiratory syndrome (SARS) caused by SARS coronavirus (SARS-CoV), which is classified by the US NIH as a category C pathogen. This vaccine is comprised of a recombinant receptor-binding domain (RBD) of the SARS-CoV spike (S) protein and formulated on alum, together with a synthetic glucopyranosyl lipid A. The vaccine would induce neutralizing antibodies without causing Th2-type immunopathology. Vaccine development is being led by the nonprofit product development partnership; Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development in collaboration with two academic partners (the New York Blood Center and University of Texas Medical Branch); an industrial partner (Immune Design Corporation); and Walter Reed Army Institute of Research. A roadmap for the product development of the RBD-S SARS vaccine is outlined with a goal to manufacture the vaccine for clinical testing within the next 5 years. Taylor & Francis 2014-01-09 /pmc/articles/PMC3586247/ /pubmed/23252385 http://dx.doi.org/10.1586/erv.12.126 Text en © 2012 Expert Reviews Ltd This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
spellingShingle Special Report
Jiang, Shibo
Bottazzi, Maria Elena
Du, Lanying
Lustigman, Sara
Tseng, Chien-Te Kent
Curti, Elena
Jones, Kathryn
Zhan, Bin
Hotez, Peter J
Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome
title Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome
title_full Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome
title_fullStr Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome
title_full_unstemmed Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome
title_short Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome
title_sort roadmap to developing a recombinant coronavirus s protein receptor-binding domain vaccine for severe acute respiratory syndrome
topic Special Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586247/
https://www.ncbi.nlm.nih.gov/pubmed/23252385
http://dx.doi.org/10.1586/erv.12.126
work_keys_str_mv AT jiangshibo roadmaptodevelopingarecombinantcoronavirussproteinreceptorbindingdomainvaccineforsevereacuterespiratorysyndrome
AT bottazzimariaelena roadmaptodevelopingarecombinantcoronavirussproteinreceptorbindingdomainvaccineforsevereacuterespiratorysyndrome
AT dulanying roadmaptodevelopingarecombinantcoronavirussproteinreceptorbindingdomainvaccineforsevereacuterespiratorysyndrome
AT lustigmansara roadmaptodevelopingarecombinantcoronavirussproteinreceptorbindingdomainvaccineforsevereacuterespiratorysyndrome
AT tsengchientekent roadmaptodevelopingarecombinantcoronavirussproteinreceptorbindingdomainvaccineforsevereacuterespiratorysyndrome
AT curtielena roadmaptodevelopingarecombinantcoronavirussproteinreceptorbindingdomainvaccineforsevereacuterespiratorysyndrome
AT joneskathryn roadmaptodevelopingarecombinantcoronavirussproteinreceptorbindingdomainvaccineforsevereacuterespiratorysyndrome
AT zhanbin roadmaptodevelopingarecombinantcoronavirussproteinreceptorbindingdomainvaccineforsevereacuterespiratorysyndrome
AT hotezpeterj roadmaptodevelopingarecombinantcoronavirussproteinreceptorbindingdomainvaccineforsevereacuterespiratorysyndrome